Therapy-related myelodysplastic syndrome in childhood: A retrospective study of 36 patients in Japan

Received 15 September 2004; accepted 29 November 2004.

Abstract

We report here a retrospective analysis of 36 children with therapy-related myelodysplastic syndrome (t-MDS) diagnosed between 1990 and 1999 in Japan. Their median age was 7.7 years and the median latency period for the development of t-MDS was 38.5 months. The primary tumors were hematologic in 15 of the cases and nonhematologic in 21. Chromosomal abnormalities were detected in 32/34(94%) patients: abnormalities of chromosomes 5and/or 7 in 41% and notably, 11q23 abnormalities in 31%. The prognosis of children with t-MDS was very poor as compared to children with primary MDS (5 year survival: 16% versus 54%, p<0.0001).

Keywords: Children, Therapy-related myelodysplastic syndrome (t-MDS), Chromosomal abnormalities, Alkylating agents, Topoisomerase II inhibitors

a Department of Pediatrics, Faculty of Medicine, Aichi Medical University, Aichi 4801195, Japan

b Department of Pediatrics, St Luke's International Hospital, Tokyo, Japan

c Department of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan

d Department of Pediatrics, Kyoto National Medical Center, Kyoto, Japan

e Division of Hematology, Kanagawa Children's Medical Center, Kanagawa, Japan

f Department of Pediatrics, School of Medicine, Kurume University, Fukuoka, Japan

g Department of Pediatric Hematology/Oncology, Narita Red Cross Hospital, Chiba, Japan

h Department of Pediatrics, Komoro Kosei General Hospital, Nagano, Japan

i Department of Pediatrics, School of Medicine, Hokkaido University, Sapporo, Japan

j Department of Pediatrics, National Kyusyu Cancer Center, Fukuoka, Japan

k Department of Pediatrics, Kagoshima City Hospital, Kagoshima, Japan

l Department of Pediatrics, Graduate School of Medicine, Nagoya University, Nagoya, Japan

m Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Corresponding author. Tel.: +81 56162 3311; fax: +81 56162 2886.

PII: S0145-2126(05)00024-X

doi:10.1016/j.leukres.2004.11.018

8 of 23